Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.

Rinner B, Froehlich EV, Buerger K, Knausz H, Lohberger B, Scheipl S, Fischer C, Leithner A, Guelly C, Trajanoski S, Szuhai K, Liegl B.

Int J Oncol. 2012 Feb;40(2):443-51. doi: 10.3892/ijo.2011.1235. Epub 2011 Oct 14.

PMID:
22002331
2.

Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1.

Scheil S, Brüderlein S, Liehr T, Starke H, Herms J, Schulte M, Möller P.

Genes Chromosomes Cancer. 2001 Nov;32(3):203-11.

PMID:
11579460
3.

[Sacrococcygeal chordoma with malignant spindle cell components. Case report and review of the literature].

Woenckhaus J, Benedix P, Holotiuk O, Riedel H, Justus J.

Pathologe. 1997 Sep;18(5):395-400. Review. German.

PMID:
9432676
4.

Sacrococcygeal chordoma with a malignant spindle cell component. A report of two autopsy cases with a review of the literature.

Fukuda T, Aihara T, Ban S, Nakajima T, Machinami R.

Acta Pathol Jpn. 1992 Jun;42(6):448-53. Review.

PMID:
1502905
5.

Microsatellite instability in sacral chordoma.

Klingler L, Shooks J, Fiedler PN, Marney A, Butler MG, Schwartz HS.

J Surg Oncol. 2000 Feb;73(2):100-3.

PMID:
10694646
6.

Epidermal growth factor receptor (EGFR) status in chordoma.

Ptaszyński K, Szumera-Ciećkiewicz A, Owczarek J, Mrozkowiak A, Pekul M, Barańska J, Rutkowski P.

Pol J Pathol. 2009;60(2):81-7.

PMID:
19886182
7.

Cytogenetic and molecular cytogenetic analysis of sacral chordoma.

Bridge JA, Pickering D, Neff JR.

Cancer Genet Cytogenet. 1994 Jul 1;75(1):23-5.

PMID:
8039159
8.

Intraosseous benign notochord cell tumors (BNCT): further evidence supporting a relationship to chordoma.

Deshpande V, Nielsen GP, Rosenthal DI, Rosenberg AE.

Am J Surg Pathol. 2007 Oct;31(10):1573-7.

PMID:
17895760
9.

Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.

Hsu W, Mohyeldin A, Shah SR, ap Rhys CM, Johnson LF, Sedora-Roman NI, Kosztowski TA, Awad OA, McCarthy EF, Loeb DM, Wolinsky JP, Gokaslan ZL, Quiñones-Hinojosa A.

J Neurosurg. 2011 Oct;115(4):760-9. doi: 10.3171/2011.5.JNS11185. Epub 2011 Jun 24.

10.

Establishment and characterization of a novel chordoma cell line: CH22.

Liu X, Nielsen GP, Rosenberg AE, Waterman PR, Yang W, Choy E, Sassi S, Yang S, Harmon DC, Yang C, Schwab JH, Kobayashi E, Mankin HJ, Xavier R, Weissleder R, Duan Z, Hornicek FJ.

J Orthop Res. 2012 Oct;30(10):1666-73. doi: 10.1002/jor.22113. Epub 2012 Apr 13.

11.
12.

Fine-needle aspiration of a chordoma and its recurrence 19 years after.

Saiz A, de Agustín P, Barrios AP, Alberti N.

Diagn Cytopathol. 2006 Sep;34(9):663-4. No abstract available.

PMID:
16900473
13.

Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.

von Witzleben A, Goerttler LT, Marienfeld R, Barth H, Lechel A, Mellert K, Böhm M, Kornmann M, Mayer-Steinacker R, von Baer A, Schultheiss M, Flanagan AM, Möller P, Brüderlein S, Barth TF.

Cancer Res. 2015 Sep 15;75(18):3823-31. doi: 10.1158/0008-5472.CAN-14-3270. Epub 2015 Jul 16.

PMID:
26183925
14.

Total resection of inferiorly located sacral chordoma with posterior only approach: case report and review of the literature.

Sabuncuoglu H, Ozdogan S, Dogan H, Ataoglu O, Tımurkaynak E.

Turk Neurosurg. 2010 Oct;20(4):527-32. doi: 10.5137/1019-5149.JTN.1776-09.3. Review.

15.

Loss of SMARCB1/INI1 expression in poorly differentiated chordomas.

Mobley BC, McKenney JK, Bangs CD, Callahan K, Yeom KW, Schneppenheim R, Hayden MG, Cherry AM, Gokden M, Edwards MS, Fisher PG, Vogel H.

Acta Neuropathol. 2010 Dec;120(6):745-53. doi: 10.1007/s00401-010-0767-x. Epub 2010 Oct 30.

PMID:
21057957
16.

Cytogenetics of sacral chordoma.

DeBoer JM, Neff JR, Bridge JA.

Cancer Genet Cytogenet. 1992 Nov;64(1):95-6. Review.

PMID:
1458457
17.

Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.

Ostroumov E, Hunter CJ.

Spine (Phila Pa 1976). 2008 Dec 1;33(25):2774-80. doi: 10.1097/BRS.0b013e31817e2d1e.

PMID:
19050584
18.

Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.

Yang H, Zhu L, Ebraheim NA, Liu X, Castillo S, Tang T, Liu J, Cui H.

Spine J. 2009 Dec;9(12):972-80. doi: 10.1016/j.spinee.2009.08.447. Epub 2009 Oct 1.

PMID:
19800296
19.

Sacral chordoma in early childhood: clinicopathological and immunohistochemical study.

Iwasa Y, Nakashima Y, Okajima H, Morishita S.

Pediatr Dev Pathol. 1998 Sep-Oct;1(5):420-6.

PMID:
9688766
20.

Clonal chromosome aberrations in three sacral chordomas.

Mertens F, Kreicbergs A, Rydholm A, Willén H, Carlén B, Mitelman F, Mandahl N.

Cancer Genet Cytogenet. 1994 Apr;73(2):147-51. Review.

PMID:
8174090
Items per page

Supplemental Content

Write to the Help Desk